A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein

✍ Scribed by Eiji Ando; Fumihiko Yamashita; Masatoshi Tanaka; Kyuichi Tanikawa

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 262 KB
• Volume: 79
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19970515)79:10<1890::aid-cncr8>3.0.co;2-k

✦ Synopsis

METHODS.

Nine patients with HCC were treated by arterial infusion of a chemotherapeutic agent via a subcutaneously implanted injection port. One course consisted 1 Second Department of Medicine, Kurume Uniof the daily administration of cisplatin (10 mg for 1 hour on Days 1-5) and the versity School of Medicine, Fukuoka-ken, Japan.

subsequent infusion of 5-fluorouracil (250 mg for 5 hours on Days 1-5). In princi-2 Department of Medicine, Saga Social Insurple, patients were to receive four serial courses of chemotherapy. ance Hospital, Saga-ken, Japan.

RESULTS.

The mean course of chemotherapy was 4.6 (range, 2.6-7.6) months. The serum total concentrations of a-fetoprotein and des-g-carboxyprothrombin were reduced after chemotherapy in most of the patients. Two patients showed complete response (CR) with disappearance of HCC and PVTT after treatment, and the other two showed partial response (PR) (response rate [CR / PR/All cases], 44.4%). The 3-year survival rate was 40%. The mean survival after the therapy was 14.9 (range, 4.1-48.9) months. The 50% survival was 9.2 months. Adverse reactions were tolerable nausea and loss of appetite.